Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn's Disease

Fast replyInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying treatments for Moderate to Severe Crohn's Disease, a condition that causes inflammation in the digestive tract, leading to symptoms like abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. The study will explore the effects of several medications, including Lutikizumab (also known as ABT-981), ABBV-382, and Risankizumab (also referred to as ABBV-066). These medications are designed to target specific parts of the immune system to help reduce inflammation and manage symptoms.

The purpose of the study is to evaluate the safety and effectiveness of these targeted therapies. Participants will receive either one of the study medications or a placebo. The study will last for a period of up to 24 weeks, during which participants will receive regular treatments and undergo various health assessments to monitor their response to the medication. The goal is to see if these treatments can help achieve endoscopic remission, which means reducing the visible signs of inflammation in the digestive tract, and clinical remission, which involves a significant reduction in symptoms.

Throughout the study, participants will be closely monitored by healthcare professionals to ensure their safety and to gather information on how well the treatments work. This research aims to provide new insights into managing Crohn's Disease and improving the quality of life for those affected by this condition.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be informed about the trial's purpose, procedures, and potential risks and benefits. You will be asked to provide informed consent, which means you agree to participate after understanding all the details.

  2. Step 2

    Initial assessment

    An initial assessment will be conducted to confirm your eligibility. This includes verifying your age, weight, and medical history related to moderate to severe Crohn's disease. A diagnosis of Crohn's disease for at least three months prior to the start of the trial is required.

  3. Step 3

    Baseline evaluation

    A baseline evaluation will be performed to assess the current state of your condition. This may involve endoscopic procedures to check for mucosal inflammation and scoring systems to measure disease activity.

  4. Step 4

    Treatment administration

    You will receive one of the study medications, which may include lutikizumab, ABBV-382, or ABBV-066 (also known as risankizumab). These medications are administered as a solution for injection or infusion. The specific route and dosage will be determined by the study protocol.

  5. Step 5

    Ongoing monitoring

    Throughout the study, regular monitoring will occur to evaluate the safety and effectiveness of the treatment. This includes scheduled visits for health assessments and possibly additional endoscopic evaluations.

  6. Step 6

    End of treatment evaluation

    At the end of the treatment period, an evaluation will be conducted to determine if the primary goal of endoscopic remission has been achieved. Secondary goals include assessing clinical remission based on symptom scores.

  7. Step 7

    Follow-up

    After completing the treatment phase, follow-up visits may be scheduled to monitor your health and any long-term effects of the treatment.

Who can join the trial?

6 criteria

  • Adults aged between 18 and 75 years old. You must also be of legal adult age according to local laws.
  • Your body weight must be at least 40 kg (about 88 pounds) at the start of the study.
  • You must have a confirmed diagnosis of Crohn's Disease (CD) for at least 3 months before starting the study. This means you need to have biopsy results that show you have CD, as checked by the study doctor.
  • Your Crohn's Disease Activity Index (CDAI) score must be 220 or higher at the start of the study. The CDAI is a way to measure how active your Crohn's Disease is.
  • You need to have endoscopic evidence of mucosal inflammation. This means a doctor has looked inside your intestines and found inflammation. The inflammation score should be 6 or higher for disease in the ileocolonic or colonic area, or 4 or higher for disease only in the ileal area. These scores are determined by a specialist who reviews the images.
  • You must have shown intolerance or an inadequate response to one or more of the following types of drugs: oral locally acting steroids, systemic steroids (like prednisone), immunomodulators, or targeted therapies (TaTs).

Who cannot join the trial?

14 criteria

  • Patients with other serious health conditions that could interfere with the study.
  • Patients who have had a recent infection that required treatment with antibiotics.
  • Patients who have had a recent surgery or are planning to have surgery during the study period.
  • Patients who are currently participating in another clinical trial.
  • Patients who have a history of allergic reactions to the study medication or similar medications.
  • Patients who are pregnant or breastfeeding.
  • Patients who have a history of substance abuse or alcohol abuse.
  • Patients who have a history of cancer, except for certain types of skin cancer.
  • Patients who have a history of heart disease or uncontrolled high blood pressure.
  • Patients who have a history of liver or kidney disease.
  • Patients who have a history of blood disorders or bleeding problems.
  • Patients who have a history of mental health disorders that are not well controlled.
  • Patients who have received certain vaccines within a specific time frame before the study.
  • Patients who are unable to comply with the study procedures or follow-up visits.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Targeted Therapy A

    is a medication being studied for its potential to help people with moderate to severe Crohn's Disease. This therapy is designed to specifically target certain pathways in the body that are believed to play a role in the inflammation and symptoms associated with Crohn's Disease. By focusing on these pathways, the medication aims to reduce inflammation and improve the overall condition of patients.

  • Targeted Therapy B

    is another treatment option being explored in this clinical trial. Like Targeted Therapy A, it is intended to address specific mechanisms in the body that contribute to Crohn's Disease. The goal of this therapy is to provide relief from the symptoms by targeting the underlying causes of inflammation, potentially leading to better management of the disease.

  • Targeted Therapy C

    is also part of the study, offering a different approach to treating Crohn's Disease. This therapy works by interacting with particular biological processes that are thought to be involved in the disease's progression. By doing so, it aims to decrease inflammation and help patients achieve a more stable and manageable condition.

What is already known about the treatment

Medication Name – This medication is administered orally in the form of tablets and is currently being studied in clinical trials for its effectiveness in treating moderate to severe Crohn's Disease. It is not yet widely available in medical practice, as it is still under investigation to determine its safety and efficacy. The medication works by targeting specific pathways in the immune system to reduce inflammation in the intestines, which is a key issue in Crohn's Disease. It belongs to a class of drugs known as targeted therapies, which are designed to specifically address the underlying causes of the disease.

Investigated diseases

Crohn's Disease – Crohn's Disease is a chronic inflammatory condition of the gastrointestinal tract, primarily affecting the small intestine and the beginning of the large intestine. It is characterized by inflammation that can penetrate deep into the layers of the bowel tissue, leading to symptoms such as persistent diarrhea, abdominal pain, and weight loss. The disease often progresses with periods of flare-ups and remission, where symptoms may subside or disappear. Over time, the inflammation can cause complications like strictures, fistulas, and malnutrition. The exact cause of Crohn's Disease is unknown, but it is believed to involve a combination of genetic, environmental, and immune system factors. The progression and severity of the disease can vary significantly among individuals.
Trial detailsLast updated 4 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-513009-30-00Protocol codeM24-885Estimated enrolment1 072 patientsSponsorAbbVie Deutschland GmbH & Co. KG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).